ArticleJournal of the Endocrine Society2022

Temozolomide Nonresponsiveness in Aggressive Prolactinomas and Carcinomas: Management and Outcomes.

Liza Das et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.